|
Abstract Details |
Titles |
|
Oral
Presentations |
|
Large B-Cell Lymphoma
|
|
Abstract #259
Saturday, 10 December
(19:00 GMT / 20:00 CET / 14:00 EST)
|
Association of Metabolic Tumor Volume (MTV) and
Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma
(LBCL) Following Axicabtagene Ciloleucel (axi-cel) Versus Standard-of-Care
(SOC) Therapy in ZUMA-7
Frederick
Locke |
|
Abstract #261
Saturday, 10 December
(19:30 GMT / 20:30 CET / 14:30 EST)
|
Durable Response to Axi-Cel CD19 Therapy is
Associated with Activation and Clonotypic Expansion of the Native T Cell
Repertoire
Giulia
Cheloni |
|
Abstract #262
Saturday, 10 December
(19:45 GMT / 20:45 CET / 14:45 EST)
|
Patients with Deleterious Germline Variants in
STXBP2 Develop Toxicity After CAR-T Cell Therapy With Axicabtagene
Ciloleucel
Mark
Leick |
|
Abstract #440
Sunday, 11 December
(14:45 GMT / 15:45 CET / 09:45 EST)
|
A Pilot Study of Axicabtagene Ciloleucel (axi-cel)
for the Treatment of Relapsed/Refractory Primary and Secondary Central
Nervous System Lymphoma (CNSL)
Caron
Jacobson |
|
Abstract #659
Sunday, 11 December
(22:30 GMT / 23:30 CET / 17:30 EST)
|
Outcomes of Subsequent Anti-Lymphoma Therapies in
Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene
Ciloleucel (axi-cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7
Study
Armin
Ghobadi
|
|
Abstract #765
Monday, 12 December
(16:00 GMT / 17:00 CET / 11:00 EST)
|
Outcomes of Axicabtagene Ciloleucel in Comparison
with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of
Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) After Two or More
Lines of Prior Therapy
Matthew
Lunning |
|
Abstract #892
Monday, 12 December
(17:30 GMT / 18:30 CET / 12:30 EST)
|
Hospital Costs and HCRU CAR T-Cell Therapy and
Hematopoietic Cell Transplant (HCT) in Patients with LBCL in the US
Chendi
Cui |
|
Acute Myeloid Leukaemia
|
|
Abstract #61
Saturday, 10 December
(15:30 GMT / 16:30 CET / 10:30 EST)
**Investigator Sponsored Research ** |
Phase I/II Study of Azacitidine (AZA) with
Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed
(ND) Older/Unfit or High-risk Acute Myeloid Leukemia (AML) and
Relapsed/Refractory (R/R) AML
Naval Davar
|
|
Abstract #603
Sunday, 11 December
(22:30 GMT / 23:30 CET / 17:30 EST)
**Investigator Sponsored Research ** |
Clinical Characteristics and Overall Survival Among
Acute Myeloid Leukemia (AML) Patients With TP53 Gene Mutation (TP53m) or
Chromosome 17p Deletion (17p del)
Naval Davar
|
|
Poster
Presentations |
|
Large B-Cell Lymphoma
|
|
Abstract #2274
Saturday, 10 December
(22:30 GMT / 23:30 CET / 17:30 EST)
|
Real-World Patient-Reported Outcomes among
Recipients of Axicabtagene Ciloleucel for R/R LBCL
Heather
S.L. Jim |
|
Abstract #2022
Saturday, 10 December
(22:30 GMT / 23:30 CET / 17:30 EST)
|
The Real-World Use of Bridging Therapy (BT) in
Relapsed or Refractory LBCL Patients Treated with CAR T-cell Therapy: A
Systematic Literature Review
Javier
Munoz |
|
Abstract #1618
Saturday, 10 December
(23:30 GMT / 18:30 EST/ Sunday, 11 December 00:30 CET)
|
Magrolimab in Combination With Rituximab +
Chemotherapy in Patients With Relapsed or Refractory (R/R) Diffuse Large
B-Cell Lymphoma (DLBCL)
Joseph Maakaron |
|
Abstract #3345
Sunday,11 December
(23:00 GMT / 18:00 EST/ Monday, 12
December 00:00 CET)
|
Real-world Impact of Time from Leukapheresis to
Infusion (Vein-to-Vein Time) in Patients with r/r LBCL Treated with Axi-cel
Frederick
Locke |
|
Abstract #3346
Sunday, 11 December
(23:00 GMT / 18:00 EST/ Monday, 12
December 00:00 CET /) |
Network Meta-Analysis (NMA) of CART-Cell Therapy for
the Treatment of R/R DLBCL After 2 Prior Treatments Using Published
Comparative Studies
Frederick
Locke |
|
Abstract #4667
Monday, 12 December
(23:00 GMT /18:00 EST/ Tuesday 13 00:00 CET)
|
Prophylactic Corticosteroid Use with Axicabtagene
Ciloleucel (axi-cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell
Lymphoma (R/R LBCL): 2-Year Follow-Up of ZUMA-1 Cohort 6
Olalekan
Oluwole |
|
Abstract #4635
Monday, 12 December
(23:00 GMT /18:00 EST/ Tuesday 13 00:00 CET)
|
ZUMA-19: A Phase 1/2 Study of Axicabtagene
Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large
B-cell Lymphoma
Olalekan
Oluwole |
|
Relapsed/Refractory Mantle Cell Lymphoma
|
|
Abstract
#4199
Monday, 12 December
(23:00 GMT /18:00 EST/ Tuesday 13 00:00 CET) |
Assessment of Durable Responses After Brexucabtagene
Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/Refractory Mantle Cell
Lymphoma (R/R MCL)
Javier
Munoz
|
|
Abstract
#4627
Monday, 12 December
(23:00 GMT /18:00 EST/ Tuesday 13 00:00 CET)
|
A Comparison of Overall Survival with Brexucabtagene
Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2)
in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)
Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)
Georg
Hess
|
|
Leukaemia
|
|
Abstract #1368
Saturday, 10 December
(22:30 GMT / 23:30 CET / 17:30 EST)
|
Updated Outcomes From the Historical Control Study
SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel
(KTE-X19) in Adult Patients With Relapsed or Refractory B-Cell Acute
Lymphoblastic Leukemia (R/R B-ALL)
Bijal
D. Shah
|
|
Abstract #3319
Sunday, 11 December
(23:00 GMT / 18:00 EST/ Mon 12 Dec 00:00 CET)
|
A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric
Antigen Receptor (CAR) T-cell Therapy, in Patients With Relapsed/Refractory
Chronic Lymphocytic Leukemia
Matthew
S. Davids |
|
Abstract #3083
Sunday, 11 December
CET / 19:00 EST)
(Mon 12 Dec 00:00 GMT / 01:00 CET/ 19:00 EST)
|
Nature of Clinical Response and Depth of Molecular
Response In Patients With TP53 Mutant Myelodysplastic Syndromes (MDS) and
Acute Myeloid Leukemia (AML) Treated With Magrolimab With Azacitidine
Lisa
Johnson
|
|
Mantle Cell & Follicular
Lymphomas
|
|
Abstract #2038
Saturday, 10 December
(22:30 GMT / 22:30 CET / 17:30 EST)
|
A 3-Year Follow-up Comparison of Clinical Outcomes
from ZUMA-5 (Axicabtagene Ciloleucel) and the International SCHOLAR-5
External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)
Paola
Ghione |
|
Abstract #1581
Saturday, 10 December
(22:30 GMT / 23:30 CET / 17:30 EST)
|
Chimeric Antigen Receptor T-Cell Therapy Setting of
Care: A Retrospective Cohort Analysis of MCL and FL Patients in the US
Roxana
Seyedin |
|
Abstract
#4861
Monday, 12 December
(23:00 GMT / 18:00 EST/ Tuesday,13 Dec 00:00 CET)
|
Cost-effectiveness of Axi-Cel for Adult Patients
with Relapsed or Refractory Follicular Lymphoma in the United States
Olalekan
Oluwole |
|
Abstract
#4660
Monday, 12 December
(23:00 GMT / 18:00 EST/ Tuesday, 13 Dec 00:00 CET)
|
3-Year Follow-Up Analysis of ZUMA-5: A Phase 2 Study
of Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory
(R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
Sattva
Neelapu |
|
Other Notable Data |
|
Abstract #165
Saturday, 10 December
(17:30 GMT / 18:30 CET / 12:30 EST)
|
Targeting CNS Lymphoma with Intravenous Axi-Cel:
Evidence for Transcriptional Evolution Towards a Prominent Interferon
Signature in CAR-T Cells Trafficking to the Tumor Site
Ulrike
Gerdemann |
|
Abstract #1981
Saturday, 10 December
(22:30 GMT / 23:30 CET / 17:30 EST)
|
Identification of IL-4 as a Key Regulator of CAR
T-Cell Exhaustion Using Functional Genomics and Correlates of the Zuma-1
Clinical Trial
Carly
Stewart |
|
Abstract #2039
Saturday, 10 December
(22:30 GMT / 23:30 CET / 17:30 EST)
|
Baseline CRP and Ferritin Identify Patients at High
Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid
Prophylaxis
Rawan
Faramand |
|
Abstract #4610
Monday, 12 December
(23:00 GMT / 18:00 EST/ Tuesday, 13 Dec 00:00 CET)
|
Immunosuppressive Monocyte Modulation of CAR T Cell
Functions and Impact on Response to CART19
Kun Yun |
|
Abstract
#4284
Monday, 12 December
(23:00 GMT / 18:00 EST/ Tuesday, 13 Dec 00:00 CET)
|
Patients of Minority Race or Ethnicity in the US
Receiving CAR T-cell Therapy in Clinical Trials and in the Real-world: A
SEER-based Simulation
Mendel
Goldfinger |
